This stock comparison examines two clinical-stage biotechnology companies operating in different corners of advanced medicine. Autolus Therapeutics develops engineered T-cell therapies for cancer and autoimmune disease, while Rocket Pharmaceuticals focuses on one-time gene therapies for rare genetic disorders. Although both are speculative, catalyst-driven equities, their fundamental profiles diverge sharply: one is scaling a commercial launch, and the other is still building toward product revenue. For traders and investors evaluating relative performance, market positioning, and risk appetite in the biotech sector, contrasting AUTL and RCKT highlights the trade-off between commercial traction and binary clinical catalysts.
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing CAR-T (chimeric antigen receptor T-cell) therapies for cancer and autoimmune diseases. Its lead product, AUCATZYL (obecabtagene autoleucel), is approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. In recent quarters, product revenue has accelerated, rising roughly 119% year over year to $45.7 million in the most recent reported quarter, and management raised full-year 2026 net product revenue guidance to between $140 million and $150 million. The company has also expanded its U.S. treatment-center footprint and begun a U.K. launch.
Recent stock behavior has reflected both enthusiasm around commercial execution and lingering concerns over ongoing net losses. Autolus reported positive gross margin for the first time in early 2026 and implemented a cost-reduction initiative affecting about 13% of its workforce. The shares trade within a relatively wide 52-week range and carry a consensus "Strong Buy" rating with an average price target well above current levels. Pipeline catalysts, including longer-term lupus data and initial data in progressive multiple sclerosis and light-chain amyloidosis, are expected through late 2026 and into 2027.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing lentiviral and AAV (adeno-associated virus) based gene therapies for rare diseases. In March 2026, the FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy approved for children with severe leukocyte adhesion deficiency-I (LAD-I), a rare immune disorder. Patient onboarding for that launch is expected to begin in late 2026, meaning the company has not yet recorded product revenue.
The company's most advanced pipeline asset is RP-A501, an investigational gene therapy for Danon disease, a rare inherited cardiac condition. In recent weeks, Rocket reached alignment with the FDA on the design of a pivotal Phase 2 study, including a 12-patient efficacy population and 12-month co-primary endpoints, after an earlier clinical hold was lifted. The company also secured up to $150 million in credit financing and sold a Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway. These regulatory milestones have driven sharp single-day moves in the shares, and analyst sentiment has improved, with several firms upgrading the stock even as others remain cautious about commercial timelines.
For investors who prefer a systematic, data-driven approach to stock selection, Tickeron's Trending AI Robots page offers a curated view of its most suitable automated strategies for current market conditions. Tickeron hosts hundreds of AI trading bots that collectively monitor thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and basket of securities. Because not every bot fits every market regime, only the strongest and most relevant strategies earn a place in the Trending AI Robots section. These bots apply algorithmic analysis to identify patterns and generate signals across both speculative biotech names and broader market segments. Exploring the Trending AI Robots page can help traders compare systematic approaches alongside their own fundamental analysis.
The clearest contrast between these two companies is stage of development. Autolus is already commercializing an approved therapy with triple-digit revenue growth, a positive gross margin, and a defined path toward profitability in its core business. Rocket, by comparison, remains pre-revenue and depends on regulatory milestones and future launch execution for its first approved product while its higher-value pipeline remains years from potential approval.
Growth drivers also differ. Autolus is expanding a marketed oncology franchise across geographies and indications, giving it more near-term visibility but exposing it to competition in a crowded CAR-T market. Rocket's value is concentrated in rare-disease gene therapies with large potential markets but binary clinical risk, as demonstrated by the earlier clinical hold on its Danon disease program.
On financial positioning, both companies have reported cash runways extending into 2028, though Autolus also generates revenue while Rocket relies on financing and voucher sales. Market sentiment has been more constructive toward Autolus, reflected in its "Strong Buy" consensus, whereas Rocket's ratings remain more mixed. From a risk standpoint, Autolus faces commercial execution and cost pressures, while Rocket faces clinical, regulatory, and timeline uncertainty.
Based on observable factors such as trend consistency, revenue visibility, and the stability of its commercial foundation, Tickeron's AI would likely favor AUTL in the current environment. Autolus presents a more defined growth trajectory with accelerating product sales, a raised revenue outlook, and constructive analyst consensus, which tends to produce steadier technical signals than a catalyst-dependent pre-revenue stock. Rocket Pharmaceuticals has meaningful upside potential tied to its Danon disease program, but its performance remains more closely tied to discrete regulatory events, introducing greater volatility and less consistent trends. This assessment is probabilistic and reflects relative positioning rather than a definitive forecast, and it should be evaluated alongside each investor's own research and risk tolerance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for AUTL moved below the 200-day moving average on November 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Moving Average Convergence Divergence Histogram (MACD) for AUTL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for AUTL entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 224 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.552) is normal, around the industry mean (3.596). P/E Ratio (-1.208) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. AUTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 72 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for RCKT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 48 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for RCKT's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.710) is normal, around the industry mean (3.596). P/E Ratio (-14.906) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AUTL | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 92 | |
PRICE GROWTH RATING 1..100 | 88 | 77 | |
P/E GROWTH RATING 1..100 | 35 | 16 | |
SEASONALITY SCORE 1..100 | n/a | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (10) in the Biotechnology industry is somewhat better than the same rating for AUTL (71). This means that RCKT’s stock grew somewhat faster than AUTL’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AUTL (100). This means that RCKT’s stock grew similarly to AUTL’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as AUTL (99). This means that RCKT’s stock grew similarly to AUTL’s over the last 12 months.
RCKT's Price Growth Rating (77) in the Biotechnology industry is in the same range as AUTL (88). This means that RCKT’s stock grew similarly to AUTL’s over the last 12 months.
RCKT's P/E Growth Rating (16) in the Biotechnology industry is in the same range as AUTL (35). This means that RCKT’s stock grew similarly to AUTL’s over the last 12 months.
| AUTL | RCKT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| Advances ODDS (%) | 13 days ago 86% | 18 days ago 80% |
| Declines ODDS (%) | 2 days ago 88% | 5 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AUTL’s FA Score shows that 0 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AUTL’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).
AUTL (@Biotechnology) experienced а -22.45% price change this week, while RCKT (@Biotechnology) price change was -15.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
AUTL is expected to report earnings on Mar 10, 2027.
RCKT is expected to report earnings on Mar 01, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To AUTL | 1D Price Change % | ||
|---|---|---|---|---|
| AUTL | 100% | -7.38% | ||
| CRSP - AUTL | 46% Loosely correlated | +0.44% | ||
| SANA - AUTL | 43% Loosely correlated | -8.62% | ||
| EDIT - AUTL | 43% Loosely correlated | -4.09% | ||
| RCKT - AUTL | 43% Loosely correlated | -7.58% | ||
| TSHA - AUTL | 43% Loosely correlated | -1.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MLPB | 27.16 | -0.48 | -1.73% |
| ETRACS Alerian MLP Infrastructure Index ETN Series B (MLPB) | |||
| DDTM | 19.53 | -0.46 | -2.31% |
| Innovator Equity Dual Directional 10 Buffer ETF - March (DDTM) | |||
| VGK | 82.61 | -1.96 | -2.32% |
| Vanguard FTSE Europe ETF (VGK) | |||
| THQ | 17.12 | -0.55 | -3.11% |
| abrdn Healthcare Opportunities Fund | |||
| ABIG | 31.73 | -1.21 | -3.67% |
| Argent Large Cap ETF (ABIG) | |||